Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-Current Deffered Revenue: 2021-2024

Historic Non-Current Deffered Revenue for ARS Pharmaceuticals (SPRY) over the last 3 years, with Dec 2024 value amounting to $1.5 million.

  • ARS Pharmaceuticals' Non-Current Deffered Revenue was N/A to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2024, which is N/A change from last year.
  • Per ARS Pharmaceuticals' latest filing, its Non-Current Deffered Revenue stood at $1.5 million for FY2024, which was down 46.32% from $2.9 million recorded in FY2022.
  • In the past 5 years, ARS Pharmaceuticals' Non-Current Deffered Revenue registered a high of $3.0 million during FY2021, and its lowest value of $1.5 million during FY2024.
  • Over the past 2 years, ARS Pharmaceuticals' median Non-Current Deffered Revenue value was $2.2 million (recorded in 2022), while the average stood at $2.2 million.
  • Data for ARS Pharmaceuticals' Non-Current Deffered Revenue shows a maximum YoY dropped of 4.74% (in 2022) over the last 5 years.
  • ARS Pharmaceuticals' Non-Current Deffered Revenue (Yearly) stood at $3.0 million in 2021, then dropped by 4.74% to $2.9 million in 2022, then reached $1.5 million in 2024.